Johnson & Johnson, Pulmonary Hypertension

Startseite
Schweiz
Allschwil
Johnson & Johnson, Pulmonary Hypertension

On Facebook we share a more personal view of us and our company culture. Community guidelines https://www.jnj.com/social-media-community-guidelines

At Johnson & Johnson, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.

Please read our community guidelines on https://www.jnj.com/social-media-community-guidelines or visit our website https://www.janssen.com/

08/08/2025

: About 1,000 new cases of (PAH) are diagnosed every year in the United States.

At Johnson & Johnson, we work to improve outcomes and transform PAH into a long-term, manageable condition so that patients can live longer, healthier lives.

23/07/2025

As a leader in (PAH), we are dedicated to making a meaningful impact on patients’ lives by offering a comprehensive portfolio of treatments that address all three foundational guideline-recommended pathways for this progressive disease.

11/07/2025

: (PAH) is a rare condition that affects blood vessels carrying blood from the heart to the lungs. Early diagnosis and treatment can make a difference.

To learn more about PAH, check out our site: https://bit.ly/44q6cJe

29/06/2025

This , we are raising awareness of this rare autoimmune disease that can lead to complications like (PAH). Let’s stand together to amplify the voices of those impacted and advocate for research that can lead to better treatments.

13/06/2025

: (PAH) is categorized into four functional classes, a commonly used term to assess the severity of the condition, evaluate the progression and to determine treatments.

We are committed to supporting the PAH community by raising awareness for this progressive disease.

Explore our curated resources here: https://www.emea.jnjwithme.com/en/pulmonary-arterial-hypertension?sf224522734=1

06/05/2025

In honor of , Johnson & Johnson’s World Headquarters tower lit up in purple to showcase our support for the community. We are proud to be a part of the global efforts to raise awareness of this progressive disease.

05/05/2025

Today on , we asked members of our leadership team to share why they are passionate about working in . Together, let’s raise awareness to make a difference in the lives of those living with this condition worldwide.

11/04/2025

: Studies show that a multidisciplinary approach
is critical in the management of (PAH) and has the potential to increase survival rates.

We are proud to provide support to help you manage the condition.

Check out our site for tips in managing this condition: https://www.emea.jnjwithme.com/en/pulmonary-arterial-hypertension?sf219204291=1

07/03/2025

: It is important to advocate for yourself when talking to your healthcare team. By openly discussing your priorities and preferences, you can work together to create a personalized treatment plan that truly reflects your needs.

This collaborative approach may not only influence your treatment goals but may also enhance your overall experience with .

Check-out our Breath In, Speak Out toolkit for tips on managing PAH: https://bit.ly/3F3K6BR

28/02/2025

This , we are raising awareness and advocating for the 300 million people worldwide living with rare diseases, including . We hope those with rare diseases feel seen, heard and supported. Together, let's break down barriers to ensure all patients are championed on their journey.

07/02/2025

:
(PAH) is a rare condition that affects each person differently. This is why it’s essential to individualize treatment goals to optimize outcomes. Tailoring therapy to address each patient’s unique needs, symptoms and health status can help improve their quality of life.

21/01/2025

: Although difficult to detect, early diagnosis and treatment are critical to helping improve life expectancy for (PAH), a condition that can oftentimes take more than two years to receive a diagnosis.

Understand the signs and symptoms of PAH: https://www.janssenwithme.com/en/pulmonary-arterial-hypertension/ph-human/what-is-pah?sf211074635=1

Adresse

Hegenheimermattstrasse 95
Allschwil
4123

Telefon

+41615656565

Webseite

https://www.janssen.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Johnson & Johnson, Pulmonary Hypertension erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.